PAVMZ News and Press, PAVmed Inc. Series Z Warrant From 02/16/24

A look at the top 10 most actives in the United States PROSHARES TRUST (SQQQ) rose 2.3% to $11.595 on volume of 119,263,238 shares Direxion Daily Semiconductor Bear 3X Shares (SOXS) rose 0.8% to $4.3323 on volume of 111,414,526 shares SoundHound AI Inc. (SOUN) rose 0.0% to $3.7601 on volu...

2023-12-04 16:32:40 ET More on Lucid Diagnostics, PAVmed, etc. PAVmed Inc. (PAVM) Q3 2023 Earnings Call Transcript Lucid Diagnostics Inc. (LUCD) Q3 2023 Earnings Call Transcript PAVmed Q3 2023 Earnings Preview PAVmed Q3 2023 Earnings Preview Seeking A...

Strategic resource reallocation, including workforce reduction and other cost-cutting measures, to prioritize near-term Lucid and Veris Health commercialization efforts Conference call to be held today at 4:30PM EDT PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), a d...

Companies to host Conference Call at 4:30 PM EDT on Tuesday, January 17, 2023 PAVmed Inc. (Nasdaq: PAVM, PAVMZ), a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors, and its majority-owned subsidiaries Lu...

License option and joint R&D agreement seek to apply Novosound’s groundbreaking flexible thin-film ultrasound technology to intravascular imaging PAVmed Inc. (Nasdaq: PAVM, PAVMZ ) (“PAVmed”), a diversified commercial-stage medical technology company...

Executes first commercial contract with leading New Jersey oncology practice PAVmed Inc. (Nasdaq: PAVM, PAVMZ ) (“PAVmed”), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, toda...

Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid” or the “Company”), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), today announced that the Compan...

EsoCheck esophageal cell sampling procedure performed on 687 patients with 98% success rate Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: P...

EsoGuard test volume increased 28% sequentially and 436% annually Conference call and webcast to be held today at 4:30 PM EDT Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid” or the “Company”), a commercial-stage, cancer preventi...

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”, the “Company”), a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors, today announced that Lishan Aklog, M.D. , PAVmed&#...